Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment 5. Debunking Myths in the US Healthcare System
Top Ten Searches
aldosteronism contrast dialysis vitamin d bicarbonate arf amyloidosis hypocalcemia renal artery husYour Article Summary
Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia
Cancer, 06/24/09
Renneville A et al. - In a study to determine whether WT1 mutations are a predictor of poor outcome in pts with acute myeloid leukemia (AML), it was reported that WT1 mutations represent an adverse prognostic factor in young adults with AML. Prospective trials should confirm the clinical relevance of WT1 mutations in relation to other prognostic factors in pts with AML.
Methods- 268 young adults (ages 15-50 yrs) with AML who were treated on the Acute Leukemia French Association 9802 trial were studied.
- WT1 exon 7 and 9 mutations were screened retrospectively by polymerase chain reaction and direct sequencing.
- Pts were assessed for presence of the fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD), FLT3-D835/I836, nucleophosmin 1 (NPM1), and CCAAT/enhancer binding protein α (CEBPA) mutations.
- WT1 mutations were identified in 14 pts (5%) and were associated with a younger age and an FLT3-ITD.
- No mutation was detected in pts who had favorable cytogenetics.
- Pts who had WT1 mutations had a shorter overall survival at 4 yrs (22% vs 56%) and a higher risk of recurrence at 4 yrs (82% vs 46%) vs pts who had wild-type WT1.
- Within the subgroup of pts who had normal karyotype AML (n=106), WT1 mutation was identified as an independent adverse prognostic factor for risk of recurrence.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09
Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09
Today in Pediatric Nephrology...keeping you current
Receive free subspecialty "5-minute updates" via email
Results of surgical treatment for renovascular hypertension in children: 30 year single centre experience
Nephrology Dialysis Transplantation, 10/30/09
New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in children
Pediatric Nephrology, 11/11/09
Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients
Pediatric Nephrology, 11/03/09
Article Search
Sponsor


See Latest Articles


